Zishenpingchan granules for the treatment of Parkinson's disease:a randomized,double-blind,placebo-controlled clinical trial

被引:6
|
作者
Qing Ye [1 ]
Xiao-Lei Yuan [1 ]
Can-Xing Yuan [1 ]
Hong-Zhi Zhang [2 ]
Xu-Ming Yang [3 ]
机构
[1] Department of Neurology,LONGHUA Hospital,Shanghai University of Traditional Chinese Medicine
[2] Department of Neurology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
[3] Acupuncture and Tuina College of Shanghai University of Traditional Chinese Medicine
基金
中国国家自然科学基金;
关键词
nerve regeneration; levodopa; motion complications; non-motor symptoms; traditional Chinese medicine treatment; artificial neural networks; Zishenpingchan granules; randomized controlled trials; neurodegenerative diseases; neural regeneration;
D O I
暂无
中图分类号
R277.7 [中医神经病学与精神病学];
学科分类号
1005 ;
摘要
Levodopa preparations remain the preferred drug for Parkinson’s disease.However,long-term use of levodopa may lead to a series of motor complications.Previous studies have shown that the combination of levodopa and Zishenpingchan granules(consisting of Radix Rehmanniae preparata,Lycium barbarum,Herba Taxilli,Rhizoma Gastrodiae,Stiff Silkorm,Curcuma phaeocaulis,Radix Paeoniae Alba,Rhizoma Arisaematis,Scorpio and Centipede) can markedly improve dyskinesia and delay the progression of Parkinson’s disease,with especially dramatic improvements of non-motor symptoms.However,the efficacy of this combination has not been confirmed by randomized controlled trials.The current study was approved by the Hospital Ethics Committee and was registered in the Chinese Clinical Trial Register(registration number:Chi CTR-INR-1701194).From December 2014 to December 2016,128 patients(72 males and 56 females,mean age of 65.78 ± 6.34 years) with Parkinson’s disease were recruited from the Department of Neurology of Longhua Hospital and Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine in China.Patients were equally allocated into treatment and control groups.In addition to treatment with dopamine,patients in treatment and control groups were given Zishenpingchan granules or placebo,respectively,for 24 weeks.Therapeutic efficacy was assessed using the Unified Parkinson’s Disease Rating Scale,on-off phenomenon,Hoehn-Yahr grade,Scales for Outcomes in Parkinson’s disease–Autonomic,Parkinson’s disease sleep scale,Hamilton Anxiety Scale,Hamilton Depression Scale,Mini-Mental State Examination,and the Parkinson’s Disease Quality of Life Questionnaire.Artificial neural networks were used to determine weights at which to scale these parameters.Our results demonstrated that Zishenpingchan granules significantly reduced the occurrence of motor complications,and were useful for mitigating dyskinesia and non-motor symptoms of Parkinson’s disease.This combination of Chinese and Western medicine has the potential to reduce levodopa dosages,and no obvious side effects were found.These findings indicate that Zishenpingchan granules can mitigate symptoms of Parkinson’s disease,reduce toxic side effects of dopaminergic agents,and exert synergistic and detoxifying effects.
引用
下载
收藏
页码:1269 / 1275
页数:7
相关论文
共 50 条
  • [21] Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial
    Gu, Si-chun
    Zhou, Jie
    Ye, Qing
    Yuan, Can-xing
    JOURNAL OF INTEGRATIVE MEDICINE-JIM, 2021, 19 (02): : 120 - 128
  • [22] Pingchan granule for depressive symptoms in parkinson's disease:A randomized, double-blind, placebo-controlled trial
    Si-chun Gu
    Jie Zhou
    Qing Ye
    Can-xing Yuan
    Journal of Integrative Medicine, 2021, 19 (02) : 120 - 128
  • [23] Transdermal Rotigotine in Early Stage Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Trial
    Mizuno, Yoshikuni
    Nomoto, Masahiro
    Kondo, Tomoyoshi
    Hasegawa, Kazuko
    Murata, Miho
    Takeuchi, Masahiro
    Ikeda, Junji
    Tomida, Takayuki
    Hattori, Nobutaka
    MOVEMENT DISORDERS, 2013, 28 (10) : 1447 - 1450
  • [24] Modafinil for the treatment of daytime sleepiness in Parkinson's disease:: A double-blind, randomized, crossover, placebo-controlled polygraphic trial
    Högl, B
    Saletu, M
    Brandauer, E
    Glatzl, S
    Frauscher, B
    Seppi, K
    Ulmer, H
    Wenning, G
    Poewe, W
    SLEEP, 2002, 25 (08): : 905 - 909
  • [25] MIRABEGRON FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE: A DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Cho, Sung Yong
    Jeong, Jin
    Kim, Janghwan
    Lee, Seong Ho
    Lee, Sangchul
    Choo, Min Soo
    Oh, Seung-June
    JOURNAL OF UROLOGY, 2020, 203 : E1023 - E1023
  • [26] A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
    Kieburtz, Karl
    McGarry, Andrew
    McDermott, Michael
    Kayson, Elise
    Harrison, Madaline
    Marder, Karen
    Walker, Francis
    MOVEMENT DISORDERS, 2013, 28 (10) : 1407 - 1415
  • [27] DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial - Reply
    Wolkowitz, OM
    Kramer, JH
    Reus, VI
    Yaffe, K
    NEUROLOGY, 2004, 62 (06) : 1030 - 1030
  • [28] Transdermal rotigotine - Double-blind, placebo-controlled trial in Parkinson disease
    Jankovic, Joseph
    Watts, Ray L.
    Martin, Wayne
    Boroojerdi, Babak
    ARCHIVES OF NEUROLOGY, 2007, 64 (05) : 676 - 682
  • [29] A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis
    Nassiri-Kashani, M
    Firooz, A
    Khamesipour, A
    Moitahed, F
    Nilforoushzadeh, M
    Hejazi, H
    Bouzari, N
    Dowlati, Y
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (01) : 80 - 83
  • [30] Atorvastatin Treatment For Pulmonary Sarcoidosis, A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Fontana, J. R.
    Moss, J.
    Stylianou, M.
    Levine, S. J.
    Barochia, A. V.
    Weir, N.
    Parrish, S.
    Lazarus, A.
    Nations, J. A.
    McKay, S.
    Browning, R.
    MacDonald, S.
    May, R.
    Haughey, M.
    McGraw, P.
    Barton, M.
    Guerriero, M.
    Jolley, C.
    Folio, L. R.
    Siegelman, J.
    Kaneshiro, R.
    Bea, V. Jolley
    Bahrami, G.
    Manganiello, V. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195